gip/glp-1 receptor agonist drugs GLP-1/GIP Agonists and Diabetic Retinopathy: What ODs Should Know Mechanisms of action of GLP-1

No commitment: Month-to-month billing

Furthermore,...

Exposures Two cohorts were assembled, with the first composed of patients who started and continued on GLP-1 receptor agonists or DPP-4 inhibitors between 1 January 2007 and 31 December 2020 and the second composed of patients who started and continued on GLP-1 receptor agonists or SGLT-2 inhibitors between 1 January 1 2013 and 31 December 2020

The reason why may be genetics

Guidelines have evolved considerably from routine medication cessation in 2023 to GLP-1 RA continuation with individualised risk assessment in 20242025, illustrating increasing acknowledgment that certain theoretical risks may be underestimated